Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

Plain-language summary

This study evaluates how analyzing EGFR gene mutations from a liquid biopsy at the time of initial diagnosis can help manage patients with advanced non-small cell lung cancer (NSCLC). Patients aged 18 and over with histologically confirmed NSCLC who have not previously been treated could take part. It was a study without a phase designation and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Institut Bergonié

Intervention

EGFR gene mutation analysis on liquid biopsy

Start date

1/1/2022

Estimated completion

1/17/2026

Countries

France

Related genes

Locations

• Angers, France
• Bordeaux, France
• Lille, France
• Lyon, France
• Nice, France
• Paris, France
• Poitiers, France
• Rennes, France
• Strasbourg, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Male or female patients aged ≥ 18 years at time of proposal study,
2. Histologically confirmed non-small cell lung carcinoma,
3. No previous treatment for NSCLC,
4. Indication to EGFR status determination following HAS recommendation,
5. Voluntary signed and dated written informed consent prior to any study specific procedure
6. Patients with a social security in compliance with the French Law.

Exclusion Criteria:

1. Treatment for advanced NSCLC started before liquid biopsy sampling.
2. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).